Published in AIDS on January 02, 2016
Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr (2016) 0.85
High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial. AIDS Res Ther (2016) 0.78
Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected women. Redox Biol (2017) 0.75
Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore) (2016) 0.75
HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr (2017) 0.75
The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection. Curr HIV/AIDS Rep (2017) 0.75
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol (1995) 9.98
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care (1998) 8.29
Long-term weight loss maintenance. Am J Clin Nutr (2005) 7.42
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab (1997) 5.84
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab (2006) 3.72
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care (2001) 3.07
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr (2005) 2.15
Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab (1998) 2.12
HIV infection and the risk of diabetes mellitus. AIDS (2009) 2.10
HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog (2014) 2.03
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS (2012) 1.36
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism (2006) 1.29
Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc (2014) 1.26
Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc (2012) 1.25
Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther (2012) 1.22
HIV infection and progression of carotid and coronary atherosclerosis: the CARE study. J Acquir Immune Defic Syndr (2011) 1.14
Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr (2006) 1.12
Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis (2010) 1.11
Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) (2008) 1.09
Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res (2003) 1.05
Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One (2013) 1.00
Soluble CD14 is a nonspecific marker of monocyte activation. AIDS (2015) 0.99
Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.98
HIV infection and cardiovascular disease in women. J Am Heart Assoc (2014) 0.97
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals. J Infect Dis (2014) 0.97
Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol (2011) 0.96
Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr (2009) 0.95
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses (2015) 0.91
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis (2014) 0.89
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig (2015) 0.86
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. Open Forum Infect Dis (2014) 0.85
Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol (1985) (2007) 0.82
Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. AIDS (2015) 0.81
High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression. J Infect Dis (2015) 0.77
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Tuberculosis. Lancet (2003) 6.39
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog (2011) 3.29
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses (2005) 2.69
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 1.79
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun (2006) 1.76
Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods (2003) 1.73
Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr (2008) 1.73
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72
Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol (2003) 1.72
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis (2008) 1.72
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis (2007) 1.69
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis (2003) 1.63
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol (2002) 1.51
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses (2007) 1.46
Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog (2007) 1.45
Naive precursors of human regulatory T cells require FoxP3 for suppression and are susceptible to HIV infection. J Immunol (2008) 1.44
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
DC-Dielectrophoretic separation of biological cells by size. Biomed Microdevices (2008) 1.39
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis (2004) 1.36
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis (2010) 1.29
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. Int J Cancer (2011) 1.29
Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire. Blood (2005) 1.28
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant. J Virol (2009) 1.22
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol (2011) 1.21
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis (2006) 1.21
On-chip counting the number and the percentage of CD4+ T lymphocytes. Lab Chip (2007) 1.20
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother (2009) 1.19
Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun (2009) 1.19
Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr (2011) 1.19
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis (2011) 1.16
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16
A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. Ann Emerg Med (2010) 1.15
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Distinct molecular mechanisms account for the specificity of two different T-cell receptors. Biochemistry (2003) 1.12
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol (2007) 1.08
Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. Am J Cardiol (2013) 1.07
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06
Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol (2012) 1.04
Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. J Allergy Clin Immunol (2006) 1.04
Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in HIV-infected women in India. PLoS One (2010) 1.03
Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol (2008) 1.02
Despite biased TRBV gene usage against a dominant HLA B57-restricted epitope, TCR diversity can provide recognition of circulating epitope variants. J Immunol (2008) 1.01
Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis (2006) 1.01
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med (2010) 1.01
Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials (2011) 1.01
Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet (2010) 0.99
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol (2011) 0.98
Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.98
Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. J Cardiol (2011) 0.98
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect (2013) 0.98
Suppression of HIV-specific and allogeneic T cell activation by human regulatory T cells is dependent on the strength of signals. PLoS One (2008) 0.97
Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. PLoS One (2009) 0.97
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
Clonotype tracking of TCR repertoires during chronic virus infections. Virology (2002) 0.96
Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol (2011) 0.96
The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat (2011) 0.96
Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology (2010) 0.96
Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes. J Biol Chem (2006) 0.96